Arvinas (ARVN) Expected to Announce Earnings on Tuesday

Arvinas (NASDAQ:ARVN) is anticipated to announce its earnings results before the market opens on Tuesday, February 25th. Analysts expect the company to announce earnings of ($1.07) per share and revenue of $62.79 million for the quarter. Parties that are interested in participating in the company’s conference call can do so using this link.

Arvinas (NASDAQ:ARVN) last released its quarterly earnings data on Tuesday, February 11th. The company reported ($0.63) earnings per share for the quarter, beating the consensus estimate of ($1.07) by $0.44. Arvinas had a negative return on equity of 33.75% and a negative net margin of 75.51%. During the same period in the prior year, the company posted ($2.53) earnings per share. On average, analysts expect Arvinas to post $-4 EPS for the current fiscal year and $-4 EPS for the next fiscal year.

Arvinas Price Performance

NASDAQ ARVN opened at $17.77 on Friday. Arvinas has a 1-year low of $16.61 and a 1-year high of $51.51. The company has a market capitalization of $1.22 billion, a P/E ratio of -6.42 and a beta of 1.88. The business has a 50 day moving average price of $18.49 and a 200 day moving average price of $22.92.

Wall Street Analysts Forecast Growth

ARVN has been the subject of several research analyst reports. Oppenheimer raised their price objective on Arvinas from $40.00 to $45.00 and gave the company an “outperform” rating in a research note on Wednesday, February 12th. Cantor Fitzgerald reissued an “overweight” rating on shares of Arvinas in a research report on Friday, February 7th. Stephens started coverage on Arvinas in a research report on Monday, November 18th. They set an “overweight” rating and a $55.00 price target for the company. HC Wainwright reissued a “buy” rating and set a $87.00 price target on shares of Arvinas in a research report on Wednesday, December 11th. Finally, Barclays dropped their price target on Arvinas from $48.00 to $32.00 and set an “overweight” rating for the company in a research report on Monday, February 3rd. Twelve equities research analysts have rated the stock with a buy rating, Based on data from MarketBeat, Arvinas has a consensus rating of “Buy” and an average target price of $60.00.

About Arvinas

Arvinas, Inc, a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. The company engineers proteolysis targeting chimeras (PROTAC) targeted protein degraders that are designed to harness the body’s own natural protein disposal system to degrade and remove disease-causing proteins.